Browse studies, page 1093

Page 1093 of 1,197, newest first. Search them all at once, ranked by relevance, in Evidence Hub.

• Combined Active Treatment in Type 2 Diabetes With NASH ClinicalTrials.gov · COMPLETED, 2025
• Canagliflozin Attenuates CMR-Quantified Myocardial Fibrosis in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk ClinicalTrials.gov · COMPLETED, 2025
• EMPagliflozin After Aortic Valve Replacement - The EMPAVR Study - A Randomized Clinical Trial ClinicalTrials.gov · COMPLETED, 2026
• Relative Bioavailability of Two Different Vicadrostat/ Empagliflozin Combinations and Investigation of the Effect of Food on the Pharmacokinetics of a Vicadrostat/ Empagliflozin Combination in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Three- Way Crossover Study) ClinicalTrials.gov · COMPLETED, 2025
• Renal and Cardiovascular Effect of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibition in Combination With Loop Diuretics in Diabetic Patients With Chronic Heart Failure ClinicalTrials.gov · COMPLETED, 2019
• Open-label, Randomized, Two-period Comparative Pharmacokinetics and Bioequivalence Study of Empagliflozin + Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany) in Healthy Volunteers Under Fed Conditions ClinicalTrials.gov · COMPLETED, 2025
• Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen ClinicalTrials.gov · COMPLETED, 2020
• A Prospective, Randomized, Open Label, Parallel, 6-month Study to Explore and Evaluate the Therapeutic Effects of Henagliflozin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients With Mild Cognitive Impairment ClinicalTrials.gov · COMPLETED, 2025
• Initiation of Angiotensin Receptor-neprilysin Inhibitor (ARNi) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): the INITIATE-HFrEF Randomized Open-label Trial ClinicalTrials.gov · COMPLETED, 2025
• Effects of Empagliflozin and Continuous Positive Airway Pressure on Sleep, Cardiac Function, Oxidative Stress Markers, and Patient-Reported Outcomes in Adults With Heart Failure and Obstructive Sleep Apnea: A Randomized Controlled Clinical Trial ClinicalTrials.gov · COMPLETED, 2025
• A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk ClinicalTrials.gov · COMPLETED, 2015
• Impact of SGLT2 on Glucosuria in HNF1A-MODY ClinicalTrials.gov · COMPLETED, 2023
• A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 and Sitagliptin Administered Orally Over 24 Weeks, in Drug naïve Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Diet and Exercise ClinicalTrials.gov · COMPLETED
• The Effect of SGLT2 Inhibition on Adipose Tissue Inflammation and Endothelial Function Pilot ClinicalTrials.gov · COMPLETED, 2023
• Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects ClinicalTrials.gov · COMPLETED, 2018
• A Phase I Study to Evaluate the Drug-Drug Interaction of Chiglitazar With Empagliflozin，Atorvastatin and Valsartan in Healthy Subjects ClinicalTrials.gov · COMPLETED, 2023
• Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet and Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets in an Open, Randomised, Single Dose, Three-period Cross-over Study in Healthy Male and Female Subjects ClinicalTrials.gov · COMPLETED
• Effect of Empagliflozin on Cardiac Output in Patients With Acute Heart Failure (EMPA Acute Heart Failure) ClinicalTrials.gov · TERMINATED, 2020
• Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (Empire Prevent: Cardiac): A Randomized Controlled Trial ClinicalTrials.gov · COMPLETED, 2025
• Randomised, Double-blind, Placebo-controlled and Parallel Dose Group Trial to Investigate Efficacy and Safety of Multiple Doses of Oral BI 690517 Over 14 Weeks, Alone and in Combination With Empagliflozin, in Patients With Diabetic and Non-diabetic Chronic Kidney Disease ClinicalTrials.gov · COMPLETED, 2023
• A Randomized, Allocation-concealed, Assessor-blinded, Parallel-group Trial Evaluating the Association Between Erectile Dysfunction and Left Ventricular Diastolic Dysfunction and Comparing the Effects of Tadalafil, SGLT2 Inhibitors, and Their Combination in Patients With Metabolic Syndrome ClinicalTrials.gov · COMPLETED, 2026
• A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2) ClinicalTrials.gov · COMPLETED, 2014
• Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial European Heart Journal, 2022
• Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial Diabetologia, 2023
• Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction Circulation Cardiovascular Imaging, 2023
• Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial Diabetes Care, 2019
• Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction Diabetes Care, 2022
• Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial Circulation, 2021
• Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme European Heart Journal, 2022
• Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study JACC. Heart failure, 2021
• The Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin Inhibits Long QT 3 Late Sodium Currents in a Mutation Specific Manner bioRxiv, 2024
• Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial European Journal of Heart Failure, 2023
• Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b Molecular Genetics and Metabolism, 2024
• Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and Migration by Suppressing Platelet-Derived Growth Factor-Related Signaling Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2024
• Empagliflozin improves renal ischemia-reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK-OPA1 pathway promotion Cellular & Molecular Biology Letters, 2023
• Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats Frontiers in Cardiovascular Medicine, 2023
• Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure Circulation, 2023
• Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial The Lancet Diabetes and Endocrinology, 2023
• SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice International Journal of Molecular Sciences, 2024
• Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom Journal of Medical Economics, 2024
• Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF) European Journal of Heart Failure, 2020
• Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) Nephrology, Dialysis and Transplantation, 2022
• Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis International Journal of Molecular Sciences, 2021
• Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects Naunyn-Schmiedeberg's Archives of Pharmacology, 2024
• Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin Blood Advances, 2024
• Empagliflozin rescues lifespan and liver senescence in naturally aged mice GeroScience, 2024
• Empagliflozin ameliorates the impaired osteogenic differentiation ability of adipose-derived stem cells in diabetic osteoporosis by activating autophagy Stem Cells, 2024
• Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials Advances in Therapy, 2024
• SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights from Frail Hypertensive and Diabetic Patients HYPERTENSION, 2022
• Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial Circulation, 2019
• Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY) Diabetes, obesity and metabolism, 2023
• Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study European Heart Journal - Cardiovascular Pharmacotherapy, 2024
• Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review Pediatric Drugs, 2024
• Effects of Empagliflozin on Progression of Chronic Kidney Disease: A Pre-Specified Secondary Analysis from the Empa-Kidney Trial The Lancet Diabetes and Endocrinology, 2023
• Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial European Journal of Heart Failure, 2024
• Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction Acta Cardiologica, 2024
• Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation Molecular Immunology, 2024
• Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes JAMA ophthalmology, 2024
• Effect of empagliflozin in peripheral diabetic neuropathy of patients with type 2 diabetes mellitus Medicina clínica (Ed. impresa), 2024
• Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia Frontiers in Pharmacology, 2024
• Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics Journal of the American College of Cardiology, 2019
• Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial European Heart Journal, 2022
• Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy Antioxidants, 2024
• Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF) Circulation, 2022
• The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice Cardiovascular Diabetology, 2024
• Effectiveness and safety of empagliflozin: final results from the EMPRISE study Diabetologia, 2024
• The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPKα/MMP9/TGF-β1/Smad pathway Biogerontology (Dordrecht), 2024
• The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin Cardiovascular Diabetology, 2021
• Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway Redox Biology, 2022
• Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function Medicina, 2024
• Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction Journal of the American College of Cardiology, 2024
• Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial The Lancet Diabetes and Endocrinology, 2023
• Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial Circulation, 2023
• SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis Metabolism: Clinical and Experimental, 2023
• Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial Cardiovascular Diabetology, 2024
• Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop Molecular Genetics and Metabolism, 2024
• Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial Diabetes, obesity and metabolism, 2024
• Attenuated Effects of Topical Empagliflozin on Imiquimod-induced Model of Psoriasis in Mice Journal of Tropical Life Science, 2024
• Empagliflozin protects the kidney by reducing toxic ALB (albumin) exposure and preventing autophagic stagnation in proximal tubules Autophagy, 2024
• Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway Acta Pharmacologica Sinica, 2024
• Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction Journal of the American College of Cardiology, 2020
• Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial Nephrology, Dialysis and Transplantation, 2024
• Empagliflozin attenuates doxorubicin-induced cardiotoxicity by inhibiting the JNK signaling pathway Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024
• Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial The Lancet, 2023
• Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes Diabetes Care, 2024
• Tailoring of an anti-diabetic drug empagliflozin onto zinc oxide nanoparticles: characterization and in vitro evaluation of anti-hyperglycemic potential Scientific Reports, 2024
• Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD – PILOT trial Cardio-Oncology, 2024
• Empagliflozin in acute myocardial infarction: the EMMY trial European Heart Journal, 2022
• Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial European Journal of Heart Failure, 2024
• Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study Cardiovascular Diabetology, 2024
• Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain Circulation: Heart Failure, 2024
• Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial JACC. Heart failure, 2024
• Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial Hepatology, 2024
• Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2 Basic Research in Cardiology, 2024
• Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure JAMA Network Open, 2024
• Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial Scientific Reports, 2025
• The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial Nature Medicine, 2022
• Empagliflozin attenuates DOX-induced cardiotoxicity by inhibiting RIPK1-mediated endoplasmic reticulum stress and autophagy Biochimica et Biophysica Acta - Molecular Basis of Disease, 2025
• Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease New England Journal of Medicine, 2024
• Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial Circulation, 2024